I527-290 ESRIF Final Report (WEB).indd - European Commission

152
Improved COLPRO systems
Development of operating procedures focusing on the particulars of CBRN threat agents in addition to ordinary chemical,
biological, and radiological poisoning (all hazards approach) taking adequate measures to keep a forensic approach and
not to destroy evidences during action
Development of standard protocol for triage, decontamination, and training programs for mass CBRN incidents
Design of a system for search and rescue, triage, and transport of contaminated victims and tracing and tracking of evacuees
and patients (mass casualties and large-scale evacuations)
Fieldable R/N biodosimetry (or fast post accident dosimetry) and chemical, biological point of care diagnosis
6.4.5 Mitigation: Broad-spectrum medical countermeasures
R&D with the aim to develop new medical treatments after CBR-exposures are mainly performed by advanced
researchers within the areas of chemistry, molecular biology, and physics. Involvement of pharmaceutical industries is
important as well.
Research to elucidate molecular mechanisms of infection for development of novel strategies for generic treatment
methods with lower selection pressure for development of resistance
Intensifi ed R&D to understand molecular mechanisms of important viral infections where priorities should be focussed on
infections where vaccination is the best option
Novel R&D approaches for identifi cation of essential host factors common to groups of viruses for recognition of novel targets
for drug development (this technology requires novel effi cient genetic screening techniques for entire eukaryotic genomes)
A synthetic biology approach with establishment of toolboxes for rapid engineering of multiple variants of viral particles
Develop and improve treatments which do not involve antibiotics, preferably group specifi c treatments (this requires that
key virulence factors common to many pathogens need to be identifi ed and evaluated as targets for drug development)
Antidote activities on stabilization, appropriate coating material and fi llers, microencapsulation, and improved logistic systems.
Development and stockpiling of antitoxins and chemotherapeutics
Research in other novel approaches for developing medical countermeasures such as proteomics, metabolomics, enzymebased
bioscavengers, oxime-based therapy, etc.
Research on potential acute and delayed adverse health eff ects from low-level exposure to nerve agents
Basic research designed to measure sensitive markers of nerve agent exposure to assure that low-level exposures are not
associated with long-term or delayed health eff ects
Development of exposure markers for C agents relevant for triage and estimation of actual exposure/uptake/excretion
6.4.6 Recovery
6.4.6.1 Decontamination and remediation
R&D in the fi eld of CBRN decontamination and land remediation requires several diff erent disciplines. Various decontamination
systems exploit physics-, chemistry-, and biology-based technologies. Furthermore, researchers and developers in the areas
ESRIF FINAL REPORT - PART 2 • Working Group: CBRN